Symyx Technologies, Inc.

Exxonmobil Chemical Patents Inc.

University of California

Dow Corning Corporation

Quad Cities Automatic Pools, Inc.

Alessa Therapeutics, Inc.

Exxonmobil Chemicals Patents, Inc.

Symyx Solutions, Inc.

Freeslate, Inc.

Dow Silicones Corporation

Keith a. Hall

Keith Hall

Gary Michael Diamond

Vince J Murphy

Thomas R Boussie

Anne Marie Lapointe

Lily Joy Ackerman

James M Longmire

Christopher Goh

Cheryl Lund

Margarete K Leclerc

Eric L Dias

Francis Charles Rix

Richard G Taylor

James Steven Tonge

John F Walzer, Jr

Loren D Lower

Ming-Shin Tzou

Avril E Surgenor

Robert Tan Li

David H McConville

Matthew Cornyn Kuchta

Xiaohong Bei

Pu Sun

William H Chandler, Jr

John Robert Hagadorn

Howard W Turner

Isy Goldwasser

Leonid Matsiev

James A W Shoemaker

Martin Devenney

Daniel Mark Giaquinta

Peter G Schultz

Laughlin G McCullough

Vincent J Murphy

Susan Jessica Schofer

Dawn E Verdugo

Kurt Friedrich Brandstadt

Simon Cook

Trevor G Frank

Scott Thomas

Pamela Munster

Carlos Schuler

Maithili Rairkar

Pujan Desai

John Maroney

Tom Boussie

Thomas Harding McWaid

Maxime D Rappaport

Margaret McLaughlin

Tobias H Casab

Maxime Daud

Timothy Marlow Boller

Mikhail Spitkovsky

James Shoemaker

Steven D Brown

Thomas Crevier

Michael Myslovaty

Andrew Cottone, Iii

Carl Edgar Whittle

Lynn Van Erden

Miroslav Petro

Xiao-dong Xiang

Kai-An Wang

Xiao-Dong Sun

Mark Micklatcher

Victor Oswaldo Nava-Salgado

Avril Surgenor

Thomas W Galbraith

Robbie Singh Sidhu

Eric Lee Kuiokalani Dias

Li Song

Gabriel Briceño

Anne M Lapointe

Gregory Hillhouse

Kurt Brandstadt

Lily J Ackerman

Matthew Kuchta

John Walzer

Matthew C Kuchta

Anne M La Pointe

Provided herein are drug implants comprising enzalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and enzalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Drug implants containing enzalutamide and methods of use thereof

Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Implantable drug delivery devices for localized drug delivery

A composition is capable of curing via condensation reaction. The composition uses a new condensation reaction catalyst. The new condensation reaction catalyst is used to replace conventional tin catalysts. The composition can react to form a gum, gel, rubber, or resin.

Titanium containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts

Iron(III) containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts

Zirconium containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts

Iron(II) containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts

A method of attaching a cabinet assembly to a spa. The method includes providing a frame that has a channel that forms a perimeter. A spa is placed on the frame such that a flange or lip of the spa extends past the perimeter created by the channel. A plurality of slats are then secured between the flange of the spa and the channel of the frame in order to form a cabinet around the spa. The spa having a pan and a toe kick secured adjacent its bottom end.

Method of attaching a cabinet assembly to a hot tub

Zinc containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts

The present invention provides a method of producing oligomers of olefins, comprising reacting olefins with a catalyst under oligomerization conditions. The catalyst can be the product of the combination of a chromium compound and a pyridyl ether compound. In particular embodiments, the catalyst compound can be used to trimerize or tetramerize ethylene to 1-hexene, 1-octene, or mixtures of 1-hexene and 1-octene.

Methods for oligomerizing olefins with chromium pyridine ether catalysts

Alternate methods for preparing functionalized pyridyl-amine products from pyridinyl starting materials are provided herein. These alternately-prepared functionalized pyridyl-amines can be used as ligands or ligand precursors in catalytic compositions, e.g., in oligomerization reactions. Methods for such reactions are also provided herein.

Methods for preparation of pyridylamines and their use in oligomerization reactions

A method of attaching a cabinet assembly to a spa. The method includes providing a frame that has a channel that forms a perimeter. A spa is placed on the frame such that a flange or lip of the spa extends past the perimeter created by the channel. A plurality of slats are then secured between the flange of the spa and the channel of the frame in order to form a cabinet around the spa.

This invention relates to a method to selectively oligomerize olefins comprising contacting olefins with: 1) at least one diaryl-substituted diphosphine ligand; 2) a chromium metal precursor; and 3) optionally, one or more activators. In a particular embodiment, the method for selectively oligomerizing olefins includes trimerizing ethylene to selectively form 1-hexene.

Phosphine ligand-metal compositions, complexes, and catalysts for ethylene trimerizations

Alternate methods for preparing functionalized pyridyl-amine products from pyridinyl starting materials are provided herein. In addition, these alternately-prepared functionalized pyridyl-amines can be used as ligands or ligand precursors in catalytic compositions, e.g. for use in alkene oligomerization reactions.

Methods for preparation of pyridylamines

Growing community of inventors

San Jose, CA, United States of America

Keith Hall